ZA201302878B - Composition for immunising agaist staphylococcus aureus - Google Patents

Composition for immunising agaist staphylococcus aureus

Info

Publication number
ZA201302878B
ZA201302878B ZA2013/02878A ZA201302878A ZA201302878B ZA 201302878 B ZA201302878 B ZA 201302878B ZA 2013/02878 A ZA2013/02878 A ZA 2013/02878A ZA 201302878 A ZA201302878 A ZA 201302878A ZA 201302878 B ZA201302878 B ZA 201302878B
Authority
ZA
South Africa
Prior art keywords
agaist
immunising
composition
staphylococcus aureus
aureus
Prior art date
Application number
ZA2013/02878A
Other languages
English (en)
Inventor
Fabio Bagnoli
Luigi Fiaschi
Ravi Mishra
Maria Scarselli
Massimiliano Biagini
Guido Grandi
Nathalie Norais
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42734088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201302878(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201302878B publication Critical patent/ZA201302878B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2013/02878A 2009-04-14 2013-04-19 Composition for immunising agaist staphylococcus aureus ZA201302878B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21270509P 2009-04-14 2009-04-14
US23407909P 2009-08-14 2009-08-14

Publications (1)

Publication Number Publication Date
ZA201302878B true ZA201302878B (en) 2013-12-23

Family

ID=42734088

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/02878A ZA201302878B (en) 2009-04-14 2013-04-19 Composition for immunising agaist staphylococcus aureus

Country Status (24)

Country Link
US (5) US8679505B2 (fr)
EP (3) EP2419129A2 (fr)
JP (5) JP5830009B2 (fr)
KR (1) KR20120034612A (fr)
CN (2) CN102647999A (fr)
AU (1) AU2010238255B2 (fr)
BR (1) BRPI1013780B8 (fr)
CA (2) CA3154626A1 (fr)
CO (1) CO6440592A2 (fr)
DK (1) DK2510947T3 (fr)
ES (1) ES2565377T3 (fr)
HR (1) HRP20160276T1 (fr)
HU (1) HUE028803T2 (fr)
IL (1) IL215593A0 (fr)
MX (3) MX2011010735A (fr)
NZ (2) NZ612315A (fr)
PH (1) PH12015500092A1 (fr)
PL (1) PL2510947T3 (fr)
RU (2) RU2508126C2 (fr)
SG (2) SG10201404076TA (fr)
SI (1) SI2510947T1 (fr)
SM (1) SMT201600117B (fr)
WO (1) WO2010119343A2 (fr)
ZA (1) ZA201302878B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1751696A4 (fr) * 2004-05-06 2010-05-05 Univ California Procede et systeme d'alignement et de classification d'images
EP2368569A3 (fr) * 2006-01-18 2012-05-02 University Of Chicago Compositions et procédés liés aux protéines des bactéries staphylocoques
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5830009B2 (ja) 2009-04-14 2015-12-09 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対して免疫化するための組成物
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
HRP20220068T1 (hr) * 2010-05-05 2022-04-15 New York University Staphylococcus aureus leukocidini, terapijski pripravci, i njihova uporaba
RS63817B1 (sr) 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
WO2012006369A2 (fr) 2010-07-06 2012-01-12 Novartis Ag Immunisation de grands mammifères à l'aide de faibles doses d'arn
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
EP2590626B1 (fr) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
EP4119155A1 (fr) 2010-08-31 2023-01-18 GlaxoSmithKline Biologicals S.A. Liposomes pegylés pour la délivrance d'arn codant pour un immunogène
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
JP2014507142A (ja) * 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス，インコーポレイテッド α溶血素オリゴペプチドを含む免疫原性組成物
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
EP2694534B1 (fr) 2011-04-08 2018-06-20 Evaxion Biotech ApS Protéines et acides nucléiques utiles dans des vaccins ciblant le staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
WO2012177658A2 (fr) * 2011-06-19 2012-12-27 New York Univeristy Procédés de traitement et de prévention d'infections à staphylococcus aureus et d'états associés
RU2609650C2 (ru) 2011-06-19 2017-02-02 Нью-Йорк Юниверсити Способ ингибирования токсичности лейкоцидина ed staphylococcus aureus у субъекта
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
CA2840989A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions de combinaisons immunogenes et utilisations de celles-ci
FR2977800B1 (fr) 2011-07-13 2014-03-14 Sanofi Pasteur Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
IN2014CN02152A (fr) * 2011-09-01 2015-09-04 Novartis Ag
EP2793939A1 (fr) * 2011-12-23 2014-10-29 Novartis AG Compositions stables destinées à l'immunisation contre le staphylococcus aureus
PL2822947T3 (pl) 2012-03-07 2017-01-31 Glaxosmithkline Biologicals Sa Sole argininowe agonisty TLR7
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
BR112014026861A2 (pt) * 2012-04-26 2018-05-15 Univ Chicago antígenos de estafilococos coagulase e métodos de seu uso
EP2872173A4 (fr) * 2012-07-10 2016-03-23 Merck Sharp & Dohme Vaccin protecteur à base de protéine sa2493 de staphylococcus aureus
JP2015532594A (ja) * 2012-08-31 2015-11-12 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
EP2890387A1 (fr) * 2012-08-31 2015-07-08 Novartis AG Protéines stabilisées pour l'immunisation contre le staphylocoque doré
DK2890394T3 (da) * 2012-08-31 2019-07-15 Glaxosmithkline Biologicals Sa Stabiliserede proteiner til immunisering mod Staphylococcus aureus
CN104582723A (zh) * 2012-08-31 2015-04-29 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
CN102993308B (zh) * 2012-09-29 2014-11-05 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用
GB201217868D0 (en) * 2012-10-05 2012-11-21 Isis Innovation Staphyolococcus aureus antigens
EA030650B1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
EP3848046A1 (fr) 2013-06-18 2021-07-14 New York University Compositions pharmaceutiques comprenant de la leucocidine e mutées
US20160368952A1 (en) 2013-12-03 2016-12-22 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
WO2015144691A1 (fr) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions destinées à l'immunisation contre staphylococcus aureus
MX2016012538A (es) * 2014-03-26 2016-12-14 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
WO2015162100A1 (fr) * 2014-04-21 2015-10-29 Novartis Ag Adjuvants de vaccins
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
CN107072946B (zh) 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
WO2016095832A1 (fr) * 2014-12-18 2016-06-23 The University Of Hong Kong Cibles immunothérapeutiques contre staphylococcus aureus
EP3061826A1 (fr) 2015-02-27 2016-08-31 Novartis AG Réplicons du flavivirus
EP3302532A4 (fr) 2015-06-05 2019-01-09 New York University Compositions et procédés en rapport avec des agents biologiques antistaphylococciques
EP3766987B1 (fr) * 2015-09-24 2023-08-02 F. Hoffmann-La Roche AG Variants de l'alpha-hémolysine
CA3000591A1 (fr) 2015-10-13 2017-04-20 Sanofi Pasteur Compositions immunogenes contre s. aureus
AU2017218768B2 (en) * 2016-02-12 2022-03-31 Janssen Pharmaceuticals, Inc. Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2018072031A1 (fr) * 2016-10-21 2018-04-26 Socpra Sciences Et Génies S.E.C. Constructions de vaccin et leurs utilisations contre des infections par staphylococcus
CN107224576A (zh) * 2017-03-06 2017-10-03 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位的疫苗及其制备方法和应用
CN110730670A (zh) * 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
CN107827961B (zh) * 2017-10-11 2020-05-26 深圳市南山区人民医院 用于金黄色葡萄球菌Staphopain B蛋白检测的B细胞抗原表位肽及其试剂盒
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
KR102205620B1 (ko) 2019-05-16 2021-01-21 한국과학기술연구원 혈중 내 극소량 존재하는 miRNA의 검출 효율의 증가 방법
CN110256556A (zh) * 2019-06-28 2019-09-20 成都欧林生物科技股份有限公司 一种耐甲氧西林金黄色葡萄球菌人免疫球蛋白及制备方法
US20240042002A1 (en) * 2019-12-31 2024-02-08 Antagonis Compositions and methods for the prevention of S. aureus infection
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112851770B (zh) * 2021-02-05 2022-10-04 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用
EP4387596A1 (fr) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Vaccins à base d'arn lyophilisés à faible dose et leurs procédés de préparation et d'utilisation
WO2023021427A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Lyophilisation de nanoparticules lipidiques (lnp) encapsulant de l'arn et leurs formulations
CN116179663B (zh) * 2023-01-30 2023-12-22 天津大学 一种基于γ-溶血素纳米孔道收缩区实现核酸单分子片段式测序的方法

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
JPH04500203A (ja) 1988-08-25 1992-01-16 ザ　リポソーム　カンパニー，インコーポレイテッド インフルエンザワクチンおよび新規なアジュバント
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
CA2006700A1 (fr) 1989-01-17 1990-07-17 Antonello Pessi Peptides synthetiques et leur utilisation comme porteurs universels pour la preparation de conjugats immunogenes convenant a la mise au point de vaccins synthetiques
EP0454781B1 (fr) 1989-01-23 1998-12-16 Chiron Corporation Cellules de recombinaison pour des therapies d'infections et de troubles hyperproliferatifs et la preparation de ces cellules
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69032284T2 (de) 1989-03-21 1998-10-08 Vical, Inc., San Diego, Calif. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
WO1991002805A2 (fr) 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
ES2144414T3 (es) 1990-12-20 2000-06-16 Arch Dev Corp The University O Control de la expresion de un gen por medio de una radiacion ionizante.
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1992015582A1 (fr) 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES SUBSTITUEES EN POSITION 1 ET SUBSTITUEES EN POSITION 2
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
WO1993025234A1 (fr) 1992-06-08 1993-12-23 The Regents Of The University Of California Procedes et compositions permettant de cibler des tissus specifiques
WO1993025698A1 (fr) 1992-06-10 1993-12-23 The United States Government As Represented By The Particules vecteurs resistantes a l'inactivation par le serum humain
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
CA2592997A1 (fr) 1992-12-03 1994-06-09 Genzyme Corporation Vecteurs pseudo-adenoviraux
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
EP0705344B8 (fr) 1993-06-24 2006-05-10 Advec Inc. Vecteurs a base d'adenovirus destines a la therapie genique
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
KR100341341B1 (ko) 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
EP0694070B1 (fr) 1993-09-15 2002-04-10 Chiron Corporation Vecteurs composes d'alphavirus recombinants
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
WO1995011700A1 (fr) 1993-10-29 1995-05-04 Pharmos Corp. Emulsions submicroniques utilisees comme adjuvants de vaccin
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996017072A2 (fr) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Vecteurs d'alphavirus de recombinaison
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU8586298A (en) 1997-07-25 1999-02-16 University Of Massachusetts Designed protein pores as components for biosensors
EP0905243A2 (fr) * 1997-08-05 1999-03-31 Smithkline Beecham Corporation Polynucleotides de Staphylococcus aureus exprimés dans des tissue infectés
EP1279401B1 (fr) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
WO1999056776A2 (fr) 1998-05-07 1999-11-11 Corixa Corporation Composition d'adjuvant et procedes d'utilisation de celle-ci
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1109576B1 (fr) 1998-08-19 2009-10-21 Baxter Healthcare SA Conjugue de proteine-polysaccharide immunogene a liaison beta-propionamido, utile comme vaccin etabli au moyen d'un polysaccharide n-acryloyle
PT1126876E (pt) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Sistemas adjuvantes e vacinas
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
EP1150918B1 (fr) 1999-02-03 2004-09-15 Biosante Pharmaceuticals, Inc. Procede de fabrication de particules therapeutiques de phosphate de calcium
EP1880735A3 (fr) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccin
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
CA2396871A1 (fr) 2000-01-20 2001-12-20 Ottawa Health Research Institute Acides nucleiques immunostimulateurs permettant d'induire une reponse immunitaire th2
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003020875A2 (fr) 2001-06-17 2003-03-13 D-Squared Biotechnologies, Inc. Polypeptides immunogenes a surfaces exposees aux staphylocoques
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003024481A2 (fr) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Emballage de substances immunnostimulatrices dans des particules de type virus : procede de preparation et utilisation correspondants
WO2003035836A2 (fr) 2001-10-24 2003-05-01 Hybridon Inc. Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AU2002365412B2 (en) 2001-11-27 2008-10-09 Anadys Pharmaceuticals, Inc. 3-Beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL164302A0 (en) 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
EP1511746A2 (fr) 2002-05-29 2005-03-09 3M Innovative Properties Company Procede permettant d'obtenir des imidazo[4,5-c]pyridin-4-amines
WO2003105769A2 (fr) 2002-06-13 2003-12-24 New York University C-glycolipide de synthese et utilisation de celui-ci pour le traitement du cancer, des maladies infectieuses et des maladies auto-immunes
CA2496246A1 (fr) 2002-08-23 2004-03-04 Chiron Corporation Inhibiteurs de la glycogene synthase kinase 3 a base de pyrrole
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP2258365B1 (fr) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Utilisation de composés organiques pour potentialiser l'immunité
JP2007502101A (ja) 2003-07-24 2007-02-08 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスに対して防御免疫応答を誘導するポリペプチド
WO2005009378A2 (fr) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides utilises pour induire une reponse immunitaire vis-a-vis du staphylocoque dore
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
WO2005079315A2 (fr) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides d'induction d'une reponse immune protectrice contre staphylococcus aureus
US20070172498A1 (en) 2004-02-27 2007-07-26 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
JP2007531768A (ja) 2004-03-31 2007-11-08 ニューヨーク・ユニバーシティ 感染症、癌および自己免疫疾患を治療するための新規な合成ｃ−糖脂質、その合成および使用
KR20070008625A (ko) 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
WO2005115113A2 (fr) 2004-05-25 2005-12-08 Merck & Co., Inc. Polypeptides permettant d'induire une reponse immunitaire de protection contre staphylococcus aureus
JP2008513010A (ja) 2004-09-17 2008-05-01 メルク エンド カムパニー インコーポレーテッド スタフィロコッカス・アウレウスに対して防御免疫応答を誘導するポリペプチド
GB0421079D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Immunogenic composition
US8445000B2 (en) * 2004-10-21 2013-05-21 Wyeth Llc Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
JP2008532483A (ja) 2005-01-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
MX2007016403A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2368569A3 (fr) 2006-01-18 2012-05-02 University Of Chicago Compositions et procédés liés aux protéines des bactéries staphylocoques
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
TW200744632A (en) 2006-06-12 2007-12-16 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
CA2667788A1 (fr) 2006-10-30 2008-12-18 The University Of Western Ontario Anti-infectieux specifiques de staphylococcus aureus
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
AU2008294038A1 (en) 2007-05-31 2009-03-05 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting S. aureus ORF0657n
US8840906B2 (en) 2007-08-31 2014-09-23 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
US8318180B2 (en) 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2208787A1 (fr) 2009-01-19 2010-07-21 Université de Liège Polypeptide d'alpha-hémolysine recombinant de Staphylococcus aureus doté d'une suppression dans le domaine de la branche et des insertions de séquences hétérologues
JP5830009B2 (ja) * 2009-04-14 2015-12-09 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対して免疫化するための組成物

Also Published As

Publication number Publication date
EP2510947B1 (fr) 2016-02-10
US9205142B2 (en) 2015-12-08
JP2022078317A (ja) 2022-05-24
RU2011146016A (ru) 2013-05-20
RU2508126C2 (ru) 2014-02-27
NZ612315A (en) 2014-10-31
MX2019003004A (es) 2019-08-05
SMT201600117B (it) 2016-07-01
MX363222B (es) 2019-03-15
WO2010119343A3 (fr) 2011-04-07
CN102647999A (zh) 2012-08-22
CO6440592A2 (es) 2012-05-15
SG10201404076TA (en) 2014-10-30
JP2020007351A (ja) 2020-01-16
PL2510947T3 (pl) 2016-09-30
AU2010238255A1 (en) 2011-11-03
JP2012523246A (ja) 2012-10-04
CN109248313B (zh) 2023-01-17
ES2565377T3 (es) 2016-04-04
PH12015500092A1 (en) 2015-12-02
RU2013154779A (ru) 2015-06-20
US20120107340A1 (en) 2012-05-03
EP3263128A2 (fr) 2018-01-03
BRPI1013780A2 (pt) 2019-07-02
NZ595689A (en) 2014-03-28
EP3263128A3 (fr) 2018-01-24
CN109248313A (zh) 2019-01-22
EP2510947A1 (fr) 2012-10-17
DK2510947T3 (en) 2016-03-21
US20160158335A1 (en) 2016-06-09
WO2010119343A2 (fr) 2010-10-21
US8632783B2 (en) 2014-01-21
AU2010238255B2 (en) 2014-10-16
JP5830009B2 (ja) 2015-12-09
BRPI1013780B1 (pt) 2021-09-14
US20140178425A1 (en) 2014-06-26
KR20120034612A (ko) 2012-04-12
SI2510947T1 (sl) 2016-05-31
CA3154626A1 (fr) 2010-10-21
IL215593A0 (en) 2011-12-29
JP2016020390A (ja) 2016-02-04
BRPI1013780B8 (pt) 2022-10-04
HRP20160276T1 (hr) 2016-04-08
JP2017193574A (ja) 2017-10-26
CA2758490C (fr) 2023-05-02
JP7109412B2 (ja) 2022-07-29
WO2010119343A8 (fr) 2012-04-26
US10195263B2 (en) 2019-02-05
US9642904B2 (en) 2017-05-09
SG175092A1 (en) 2011-11-28
HUE028803T2 (en) 2017-01-30
EP2419129A2 (fr) 2012-02-22
US20120093850A1 (en) 2012-04-19
CA2758490A1 (fr) 2010-10-21
US20170340720A1 (en) 2017-11-30
MX2011010735A (es) 2012-01-25
US8679505B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
ZA201302878B (en) Composition for immunising agaist staphylococcus aureus
IL274109A (en) Staphylococcus aureus leukocyte killers, medicinal preparations, and their use
HK1246216B (zh) 抗微生物組合物
GB2473460B (en) Antimicrobial Composition
EP2725900A4 (fr) Composition antimicrobienne
HK1174573A1 (en) Device for hand disinfection
EP2549993A4 (fr) Compositions antimicrobiennes
ZA201305193B (en) Antimicrobial composition
IL226294A0 (en) A processed antimicrobial preparation @ Behamsa
EP2460405A4 (fr) Agent antibactérien
GB0909030D0 (en) Antibacterial composition
GB2472315B (en) Antibacterial compositions
ZA201307018B (en) Antimicrobial composition
GB201022132D0 (en) Anti-microbial composition
GB0919690D0 (en) compositions for immunising against staphylococcus aureus
ZA201403911B (en) Antimicrobial composition
ZA201404098B (en) Antimicrobial composition
ZA201403913B (en) Antimicrobial composition
ZA201403910B (en) Antimicrobial composition
ZA201403912B (en) Antimicrobial composition
ZA201403700B (en) Antimicrobial composition
GB0901693D0 (en) Antimicrobial composition
GB0910411D0 (en) Antibacterial compositions
GB201115658D0 (en) A composition for anti-microbial use
GB0922421D0 (en) Novel antimicrobial compounds